{"public_id":"co_bff3d4453c16bca060cadefac9a1070d","status":"active","merged_into_public_id":null,"resolved_public_id":"co_bff3d4453c16bca060cadefac9a1070d","name":"bevacizumab","description":"A monoclonal antibody that inhibits vascular endothelial growth factor and is used as an antiangiogenic cancer therapy.","aliases":["Avastin"],"types":["drug","therapeutic agent"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":25407135,"title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.","citation_count":2341,"url":"https://sah.borca.ai/papers/25407135"}],"claims":[{"public_id":"cl_29c8815ef5a5470ef8afa05aafdd1c17","text":"Adding bevacizumab to FOLFOX4 increases overall survival in previously treated metastatic colorectal cancer.","corpus_id":25407135,"url":"https://sah.borca.ai/claims/cl_29c8815ef5a5470ef8afa05aafdd1c17"},{"public_id":"cl_4e224afb12399621dc051e6b46b2a6ca","text":"Adding bevacizumab to FOLFOX4 improves the overall response rate compared with FOLFOX4 alone in previously treated metastatic colorectal cancer.","corpus_id":25407135,"url":"https://sah.borca.ai/claims/cl_4e224afb12399621dc051e6b46b2a6ca"},{"public_id":"cl_906d2bcc5e73ed37217c64cca8f54f3f","text":"Bevacizumab is associated with hypertension, bleeding, and vomiting.","corpus_id":25407135,"url":"https://sah.borca.ai/claims/cl_906d2bcc5e73ed37217c64cca8f54f3f"},{"public_id":"cl_ba2933a5697d635248d412396335d117","text":"Adding bevacizumab to FOLFOX4 increases progression-free survival compared with FOLFOX4 alone in previously treated metastatic colorectal cancer.","corpus_id":25407135,"url":"https://sah.borca.ai/claims/cl_ba2933a5697d635248d412396335d117"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_bff3d4453c16bca060cadefac9a1070d","url":"https://sah.borca.ai/concepts/co_bff3d4453c16bca060cadefac9a1070d"}